Monitoring Visit

1. lut 28, 2025

What Does the 'Monitoring Visit’ Mean?

A monitoring visit is an on-site evaluation conducted by a clinical research associate (CRA) at a study site participating in a clinical trial. During this visit, the CRA reviews study-related activities, documentation, and procedures to ensure compliance with the protocol, good clinical practice (GCP), and regulatory requirements.

The primary purpose of a monitoring visit is to verify the quality and integrity of the data collected, as well as to assess the overall conduct of the study at the site. These visits typically involve reviewing source documents, case report forms, informed consent forms, and other essential study documents to identify and address any issues or discrepancies.

Why Is the 'Monitoring Visit’ Important in Clinical Research?

Monitoring visits are crucial for maintaining the quality and integrity of clinical trials. They provide a mechanism for sponsors and regulatory bodies to oversee study conduct, ensuring adherence to protocols and protection of participant rights and safety.

These visits play a vital role in identifying and addressing issues early, potentially preventing protocol deviations or violations that could compromise study results. By facilitating ongoing communication between sponsors and study sites, monitoring visits contribute to the overall success and credibility of clinical research.

Good Practices and Procedures

1. Conduct a thorough review of the Investigator Site File (ISF) to ensure all essential documents are present, up-to-date, and properly maintained.
2. Perform a detailed comparison of source documents against entered data to verify accuracy and completeness, focusing on critical data points such as eligibility criteria, adverse events, and primary efficacy endpoints.
3. Assess the site’s adherence to the delegation of authority log, confirming that only authorized personnel are performing study-related tasks and that appropriate training documentation is in place.
4. Evaluate the site’s drug accountability processes, including proper storage conditions, accurate dispensing records, and appropriate handling of returned or unused investigational products.
5. Conduct interviews with key study personnel to assess their understanding of the protocol, GCP principles, and site-specific procedures, addressing any knowledge gaps or misconceptions identified.

Related Terms

• Training Compliance
• Primary Endpoint
• Competitive Intelligence